Neural mechanisms of psychedelic visual imagery
In a double-blind, placebo-controlled crossover fMRI study using dynamic causal modelling, 0.2 mg/kg psilocybin increased self-inhibition (reduced synaptic gain) in both early and higher visual areas while reducing inhibitory influence from visual-association regions onto early visual cortex, indicating enhanced top‑down feedback. These connectivity changes correlated with reports of eyes-closed visual imagery, suggesting psilocybin shifts the balance of cortical processing to amplify internally generated visual experiences.
Authors
- Franz Vollenweider
- Katrin Preller
- Adeel Razi
Published
Abstract
Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence suggests agonism of the 5-HT2A receptor may reduce synaptic gain to produce psychedelic-induced imagery. However, this has not been investigated in humans. To infer the directed connectivity changes to visual connectivity underlying psychedelic visual imagery in healthy adults, a double-blind, randomised, placebo-controlled, cross-over study was performed, and dynamic causal modelling was applied to the resting state eyes-closed functional MRI scans of 24 subjects after administration of 0.2 mg/kg of the serotonergic psychedelic drug, psilocybin (magic mushrooms), or placebo. The effective connectivity model included the early visual area, fusiform gyrus, intraparietal sulcus, and inferior frontal gyrus. We observed a pattern of increased self-inhibition of both early visual and higher visual-association regions under psilocybin that was consistent with preclinical findings. We also observed a pattern of reduced inhibition from visual-association regions to earlier visual areas that indicated top-down connectivity is enhanced during visual imagery. The results were analysed with behavioural measures taken immediately after the scans, suggesting psilocybin-induced decreased sensitivity to neural inputs is associated with the perception of eyes-closed visual imagery. The findings inform our basic and clinical understanding of visual perception. They reveal neural mechanisms that, by affecting balance, may increase the impact of top-down feedback connectivity on perception, which could contribute to the visual imagery seen with eyes-closed during psychedelic experiences.
Research Summary of 'Neural mechanisms of psychedelic visual imagery'
Introduction
Stoliker and colleagues situate the study within longstanding questions about how internally generated visual imagery is produced by the brain, and how classic serotonergic psychedelics such as psilocybin alter visual experience. The introduction contrasts externally driven perception with internally generated imagery and highlights that psychedelics can reliably produce vivid, eyes-closed visual hallucinations in healthy participants, providing an experimental model to probe the neuropharmacology and large-scale connectivity of the visual system. Preclinical findings implicating 5-HT2A receptor (5-HT2AR) agonism in reduced synaptic gain and altered sensory drive are presented as a mechanistic lead, alongside human observations of altered occipital-parietal alpha oscillations and changes in posterior versus frontal functional synchrony under psychedelics. The study set out to test how psilocybin alters directed (effective) connectivity within a small visual-imagery network comprising the early visual area (EVA), fusiform gyrus (FG), intraparietal sulcus (IPS) and inferior frontal gyrus (IFG). Based on preclinical work suggesting reduced synaptic gain under 5-HT2AR agonism, the investigators hypothesised increased self-inhibition (i.e. reduced synaptic gain) across these regions and reduced excitatory feedforward connectivity under psilocybin, with EVA self-connectivity linked to elementary imagery and top-down directed connectivity linked to complex imagery. The focus on eyes-closed resting-state scans emphasises mechanisms of internally generated imagery rather than stimulus-driven perception.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Stoliker, D., Preller, K. H., Novelli, L., Anticevic, A., Egan, G. F., Vollenweider, F. X., & Razi, A. (2025). Neural mechanisms of psychedelic visual imagery. Molecular Psychiatry, 30(4), 1259-1266. https://doi.org/10.1038/s41380-024-02632-3
References (22)
Papers cited by this study that are also in Blossom
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · Biological Psychiatry (2024)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · Biological Psychiatry (2023)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Show all 22 referencesShow fewer
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Kometer, M., Cahn, B. R., Andel, D. et al. · Biological Psychiatry (2011)
Roseman, L., Sereno, M. I., Leech, R. et al. · Human Brain Mapping (2016)
Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)
Schmidt, A., Kometer, M., Bachmann, R. et al. · Psychopharmacology (2012)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Safron, A., Juliani, A., Reggente, N. et al. · Neuroscience of Consciousness (2025)
Kaelen, M., Roseman, L., Kahan, J. et al. · European Neuropsychopharmacology (2016)
Ross, S., Malone, T. C., Mennenga, S. E. et al. · Frontiers in Pharmacology (2018)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Cited By (1)
Papers in Blossom that reference this study
Stoliker, D., Novelli, L., Khajehnejad, M. et al. · Biorxiv (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.